Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bavarian Nordic ASCHIX:BAVAC 74 Equity-to-Asset is 0.90 as of Mar. 2026, which is 27% above its 10-year median of 0.71. GuruFocus rates CHIX:BAVAC with a GF Score™ of 74/100 and a GF Value™ of kr170.09. The stock has 2 warning signs investors should review. Among 1,415 Biotechnology companies, Bavarian Nordic AS ranks better than 82.97% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bavarian Nordic AS's Total Stockholders Equity for the quarter that ended in Mar. 2026 was kr12,688 Mil. Bavarian Nordic AS's Total Assets for the quarter that ended in Mar. 2026 was kr14,102 Mil.
Therefore, Bavarian Nordic AS's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.90.
The historical rank and industry rank for Bavarian Nordic AS's Equity-to-Asset or its related term are showing as below:
CHIX:BAVAc'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27 Med: 0.71 Max: 0.9
Current: 0.9
During the past 13 years, the highest Equity to Asset Ratio of Bavarian Nordic AS was 0.90. The lowest was 0.27. And the median was 0.71.
CHIX:BAVAc's Equity-to-Asset is ranked better than 82.97% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs CHIX:BAVAc: 0.90
Bavarian Nordic AS (CHIX:BAVAc) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Bavarian Nordic AS Equity-to-Asset Related Terms
Bavarian Nordic AS Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Bavarian Nordic AS's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BAVAC vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Bavarian Nordic AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bavarian Nordic AS (CHIX:BAVAC) has a Equity-to-Asset of 0.90 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Bavarian Nordic AS and its competitors. This is 27% above median its historical median of 0.71. Over the past decade, Bavarian Nordic AS's Equity-to-Asset has ranged from 0.27 to 0.90. According to the industry distribution chart, Bavarian Nordic AS ranks #241 out of 1415 companies in the Biotechnology industry, placing it in the top 17%.
Is Bavarian Nordic AS's Equity-to-Asset too high?
Bavarian Nordic AS's current Equity-to-Asset of 0.90 is 27% above median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 0.90. The Biotechnology industry median Equity-to-Asset is 0.68. Bavarian Nordic AS's value of 0.90 is 32.4% above this industry median. Based on the distribution chart, Bavarian Nordic AS ranks #241 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bavarian Nordic AS has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #241 out of 1415 companies for Equity-to-Asset. This places Bavarian Nordic AS in the top 17% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Bavarian Nordic AS's value of 0.90 is 32.4% above this benchmark. Historically, Bavarian Nordic AS's own Equity-to-Asset has ranged from 0.27 to 0.90 over the past decade. While the company's 10-year median is 0.71 vs. the industry median of 0.68, Bavarian Nordic AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bavarian Nordic AS's current Equity-to-Asset of 0.90 is 32.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Bavarian Nordic AS and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bavarian Nordic AS's current Equity-to-Asset is 0.90, which is 27% above median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Bavarian Nordic AS (CHIX:BAVAC) has a current Equity-to-Asset of 0.90. The stock's GF Value™ is kr170.09, compared to a current price of kr188.30 — trading 10.7% above its estimated fair value. The current Equity-to-Asset is 0.90, which is 27% above median its 10-year median of 0.71 and 32.4% above the Biotechnology industry median of 0.68. Bavarian Nordic AS's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current Equity-to-Asset is 0.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr188.30 is trading 10.7% above its estimated GF Value™ of kr170.09.
Key valuation signals for CHIX:BAVAC:
Equity-to-Asset: 0.90 (27% above median its 10-year median of 0.71)
GF Value™: kr170.09 vs. price of kr188.30 (10.7% above fair value)
Industry Position: 32.4% above the Biotechnology median (#241 of 1415)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
74GF Score
Get the complete analysis for CHIX:BAVAC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
